Health
A Call for Nuance in Cardioprotection With Early Breast Cancer Therapy – MedPage Today
Longer-term PRADA trial results weigh in for low-risk group
For low-risk breast cancer patients getting potentially cardiotoxic treatment, candesartan’s (Atacand) short-term protection of cardiac function faded longer term in the PRADA trial.
Left ventricular ejection fraction (LVEF) declined a similar amount from baseline to 23 months post-randomization for patients given candesartan during adjuvant breast cancer treatment versus those who were not (1.7 vs 1.8 percentage points, P=0.91), reported Siri Heck, MD, PhD, of Akershus University Hospital in Lørenskog,…
-
Noosa News24 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
General23 hours agoPort’s lease a ‘mistake’ as major parties flag takeover
-
Business22 hours agoThese ASX 200 shares could rise 50% to 60%
-
General21 hours agoAustralia’s Myanmar community mourns earthquake losses